Although all of the 44 patients underwent initial immunosuppression maintenance with Sirolimus, because of the appearance of severe side effects such as ovarian cysts, mouth ulcers and peripheral edema in 6 patients, treatment with this mTOR inhibitor was suspended after a median of 5.56 years (range 0.81–7.76 years) and replaced with the calcineurin inhibitor Tacrolimus and mycophenolate mofetil (MMF). This evidence concerns the gene MTOR and Oral ulcer.